To test the potential use of the anti-TK1-sdAb antibodies for the immunotargeting of cancer cells that express mTK1, we co-cultured tumor cells expressing high levels of TK1 with human MNCs, added anti-TK1-sdAb-Fc antibodies and monitored the ADCC response over time. Here, MAP3K4 is linked to cancer.